Search 

20/20 GeneSystems, headquartered in Rockville, Maryland (outside of Washington, D.C.), is a revenue stage diagnostics company that uses machine learning algorithms to greatly improve the accuracy of laboratory tests for the early detection of cancer and other diseases.  In the most recent calendar year our revenues grew to over $2 million aided by several COVID-19 tests that we are successfully commercializing. 

Our multi-cancer early detection blood test (www.OneTest.Ai) measures tumor antigens and uses a machine learning algorithm powered by outcome data from over 230,000 individuals tested in real-world screening settings.  OneTest is a highly accessible and affordable pre-test that can be followed up with more expensive and specific circulating tumor DNA tests such as those being developed by Grail and Thrive Earlier Detection.  (Those companies were recently acquired for $8 billion and $2 billion respectively.)      

20/20’s institutional investors include Ping An, one of the largest digital health and insurance companies in China, and several well-regarded American funds.   We are working to an initial public offering in 2021 and are now lining up IPO “crossover” investors.

Ananda Devices is a biotech company specialized in in vitro assay developments. Leveraging our proprietary nano-organization technology, we have developed physiologically relevant in vitro models that generate predicative responses early on in the compound development processes, thereby accelerating compound discovery and de-risking key developmental investments.
Our nervous on-a-chip technology enables clients to perform drug screening, toxicity and efficacy testing up to 50x faster and 90% more cost-effective. We have 20+ years of experience in neuroscience and tissue engineering, and we have been a developer of unique devices to grow brain, spinal cord and innervated skin models for clients in 12 countries.

Our product:
NeuroHTSTM is a first-in-class high throughput screening (HTS) platform to rapidly cultivate over 3,000 CNS or PNS neurons/plate into physiologically relevant networks.
Its easy-to-use technology requires no additional equipment such as shakers and tubing.
It is compatible with most automation solutions, suitable for both and human/animal models

Our customized services:
Our core technology enables 4 types of innovative assay developments:
-Organization of cell and tissue types for reproducible and physiologically relevant in vitro testing
-Innervation of different tissues
-Miniaturization of existing models to increase throughput and sensitivity
-Development of complex co-culture models to mimic disease on-a-chip

BIOS is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals. We have leveraged recent breakthroughs in AI and Machine Learning to translate the “language” of the nervous system for the first time. Being able to precisely link nerve activity to specific conditions through the discovery of their neural biomarkers is nothing short of a game-changer, holding the key to new treatments for conditions including heart disease and diabetes.

To find out more, contact us at partnerships@bios.health.